
|Articles|February 1, 2004
No formulary should restrict itself to one SSRI for treatment of depression
Experts say SSRIs tend to have similar efficacy but different side effect profiles, and patients who don't respond to one might respond to another
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
UC Davis develops new drug for bladder cancer patients
3
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
4
Phase 3 trial launches for novel antibody targeting integrin beta-6 in advanced lung cancer
5



















































